

<b>Notice of References Cited</b>		Application/Control No.	Applicant(s)/Patent Under Reexamination 10/785,369 WAN ET AL.	
		Examiner Maury Audet	Art Unit 1654	Page 1 of 1

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2003/0045004 A1	03-2003	Barri et al.	436/518
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	U	Roberts et al. Ibuprofen, a putative anti-cataract drug, protects the lens against cyanate and galactose. Exp. Eye Res. Vol. 50 (1990), pgs. 157-164 (See document in related PCT/US2004/005374).
*	V	Lewis et al. Bendazac prevents cyanate binding to soluble lens proteins and cyanate-induced phase-separation opacities in vitro:a poss. mechanism by which bendazac could delay cataract. Exp. Eye Res.Vol.43 (1986) , pgs. 973-979 (In PCT/US2004/00537).
*	W	Crompton et al. Aspirin prevents carbamylation of soluble lens proteins and prevents cyanate-induced phase separation opacities in vitro:a poss. mechan. by which aspirin could prevent cataract. Exp. Eye Res.Vol.40 (1985),pgs.297-311 (In PCT/US2004/00537).
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.